Low-intensity focused ultrasound with microbubbles enhances CD20 monoclonal antibody delivery across the blood-brain barrier in primary central nervous system lymphoma
LIFU combined with microbubbles improves therapeutic efficacy in primary central nervous system lymphoma, suggesting a novel approach for drug delivery.
Key Points
To assess the effectiveness of low-intensity focused ultrasound and microbubbles in enhancing drug delivery across the blood-brain barrier for treating PCNSL.
Used a PCNSL model in BALB/c mice via intracranial inoculation of lymphoma cells.
Monitored tumor growth using bioluminescence imaging over 21 days post-treatment.
Evaluated treatments with control, CD20 mAb alone, LIFU with microbubbles, and combination therapy.
Analyzed drug penetration in CSF and assessed BBB permeability with Evans blue dye.
Significant tumor regression (81.3% reduction) with combined therapy (LIFU + CD20 mAb + microbubbles).
Improved CSF rituximab levels (38.6 ng/mL) in treated group compared to CD20 mAb alone (0.3 ng/mL).
Control group showed rapid tumor growth and 100% mortality by day 21 without BBB disruption.
LIFU and microbubbles alone had no significant impact on tumor growth compared to the control group.